Fig. 1From: Experiences and consequences of phasing out substances of concern in a multinational healthcare companyThe current regulatory process related to SVHCs under the REACH regulation, which may ultimately lead to a substance becoming subject to authorisation and/or falling under a restriction [7]Back to article page